Compare Summit Therapeutics Inc (SMMT) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Unity Software Inc — how do they compare? Summit Therapeutics Inc trades at $17.51 (market cap $13.98B), while Unity Software Inc trades at $42.01 (market cap $18.72B). The key difference: Unity Software Inc is the larger of the two by market cap, and Unity Software Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | U | |
|---|---|---|
Market Cap | $13.98B | $18.72B |
Sector | Health | Technology |
52-Week High | $26.38 | $49.47 |
52-Week Low | $12.43 | $17.13 |
Enterprise Value | $13.31B | $18.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion in 2025, with negative ROE and ROA, while P/B stands at 22.19. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancer, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.18 suggesting 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish with 61% buy ratings, but the stock remains speculative due to its pre-revenue status and dependence on a single drug candidate.
Unity Software (U) trades at $42.75, up 2.62% on the day, with a bullish technical outlook supported by moving averages and key support at $41. The company reported Q2 2026 EPS of -$0.05, beating expectations, but maintains negative net income margins. Revenue remains stable near $1.85B in 2025, with strategic segments like Unity Ads showing strong growth. Analyst sentiment is overwhelmingly positive, with 22 of 27 ratings being Buy and a consensus price target of $47.45.
The stock presents a growth opportunity driven by improving operational cash flow and analyst optimism, but risks include persistent unprofitability, high debt levels, and insider selling. Investors should weigh the potential for margin expansion against execution challenges in a competitive tech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
